semaglutide pathway activates a meal termination pathway. (A) c-Fos activation GLP-1 Receptor Signaling and Oral

CXCL10 antibody injection in tumor-bearing mice Three groups were established: the CTR group, the M (MCA205) group, and the CM (anti-CXCL10 antibody + MCA205) group

This is the proportion observed in the SURMOUNT-1 tirzepatide trial across age, sex, and weight-loss subgroups, and was similar for placebo participants who lost weight without medication 2

Liraglutide (a daily injection) showed more modest results, with average weight loss of about 4-5% based on 24 trials (9 937 participants)

Participants and investigators knew which drug was being administered

Is that patent laws for peptides kind of suck because you can add on one amino acid, you can modify one thing on it and suddenly it's a different compound